Travel Subsidy Now Offered to Crohn’s Trial Participants
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced that it has received ethics approval to
First Patient Enrolled in Phase 1/2 Crohn’s Clinical Trial
Vancouver, British Columbia – June 11, 2013 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system,
New IBD Advisory Team Formed
Vancouver, British Columbia – May 30, 2013 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune
Qu Biologics launches treatment trial for Crohn’s disease
Vancouver, BC – Canadian participants are being sought for a new Health Canada-approved clinical trial for the treatment of Crohn’s disease, the Vancouver-based biopharmaceutical company Qu